Analyst Jeet Mukherjee from BTIG maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) and keeping the price target at $125.00.
Jeet Mukherjee’s rating is based on several promising developments at Viking Therapeutics. The company is advancing its VK2735 program, with a Phase 2 trial expected to yield significant weight loss results, potentially exceeding 8% at 13 weeks, which would position it competitively in the obesity treatment market. Additionally, the initiation of Phase 3 trials for the subcutaneous version of VK2735, targeting both general obesity and obesity with Type 2 diabetes, further strengthens the company’s pipeline.
Furthermore, Viking Therapeutics is exploring a monthly dosing option for VK2735, which could enhance patient compliance and market appeal. The company’s amylin program, with an IND expected in the second half of 2025, also adds to its growth potential. Financially, Viking is well-positioned with substantial cash reserves to support its ongoing and future trials. These factors collectively contribute to Mukherjee’s positive outlook and Buy rating for Viking Therapeutics.
Mukherjee covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Viking Therapeutics, and Nurix Therapeutics. According to TipRanks, Mukherjee has an average return of -17.2% and a 25.00% success rate on recommended stocks.
In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $118.00 price target.